脑深部刺激器再植入后感染复发
该研究回顾性分析19年间单术者558例DBS手术,37例(6.6%)发生感染,全部取出系统并予4-6周静脉抗生素及至少30天监测后,25例再植入,22例成功;4例脑炎患者中3例再植入后伤口感染复发,脑炎后再感染OR为28.5(95%CI 1.931-420.5,p=0.007)。
要点
- 558例DBS手术中37例(6.6%)发生感染,以甲氧西林敏感金黄色葡萄球菌、肠杆菌属或凝固酶阴性葡萄球菌为主。
- 25例再植入DBS系统,22例成功,3例失败均为既往脑炎患者。
- 脑炎后DBS再植入再感染风险显著升高,OR 28.5(95%CI 1.931-420.5,p=0.007)。
核心结论
- 多数DBS感染患者取出系统并抗生素治疗后可成功再植入且无感染复发,但DBS相关脑炎患者再植入后再感染风险近乎增加30倍。
研究设计与样本
- 回顾性分析单术者19年间所有DBS手术患者,共558例,记录感染病原体、部位、治疗方案、再植入及长期结局。
主要发现
- 558例中37例(6.6%)发生感染,以甲氧西林敏感金黄色葡萄球菌、肠杆菌属或凝固酶阴性葡萄球菌为主。
- 4例脑炎、1例脑膜炎,其余为囊袋或头皮软组织感染;全部取出整个DBS系统,予4-6周静脉抗生素并额外监测至少30天。
- 25例再植入DBS系统,22例成功;4例脑炎患者中3例再植入后出现伤口感染,其余22例无复发。
- 脑炎后再植入发生再感染的OR为28.5(95%CI 1.931-420.5,p=0.007)。
关键数值与推荐
- 感染后全部取出DBS系统,予4-6周静脉抗生素,并监测复发至少30天。
临床怎么用
- 作者认为多数DBS感染患者可成功再植入且无复发,但脑炎患者再植入后再感染风险近乎增加30倍,文中讨论了针对这些患者的替代策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy of deep brain stimulation (DBS) in treating the symptoms of movement disorders can be life changing for patients. Thus, the 5%-15% incidence of stimulator-related infection requiring removal of the device can be particularly disheartening. Although DBS system reimplantation is generally successful, this is not always the case. The literature is replete with publications describing the incidence of infection and the associated features. However, the literature is sparse in terms of information on the incidence of recurrent or recrudescent infection after system reimplantation. The goal of this paper was to evaluate factors leading to unsuccessful reimplantation of a DBS system following initial infection. METHODS: Data were reviewed for all DBS procedures performed by one surgeon (K.L.H.) over 19 years including the infectious agent, location of infection, treatment regimen, and subsequent reimplantation of a DBS system and long-term outcome. RESULTS: In this series of 558 patients who had undergone DBS surgery, 37 (6.6%) subsequently developed an infection. Infections with methicillin-sensitive Staphylococcus aureus, Enterobacter species, or coagulase-negative staphylococci were predominant. Four patients had cerebritis, one had meningitis, and the rest had soft tissue infections of the pocket or scalp. All had their entire DBS system explanted, followed by 4-6 weeks of intravenous antibiotics and surveillance for recrudescence for an additional period of at least 30 days. Twenty-five patients subsequently underwent DBS system reimplantation, and the procedure was successful in 22. Three of the 4 patients with cerebritis developed a subsequent wound infection after system reimplantation. None of the other 22 patients developed a recurrence. The odds ratio for developing a recurrent infection after cerebritis was 28.5 (95% CI 1.931-420.5, p = 0.007). CONCLUSIONS: This study, the largest series of DBS system reimplantations following infection, demonstrated that most patients can have successful reimplantations without recurrent infection. However, patients who have had DBS-related cerebritis have a nearly 30-fold increased risk of developing reinfection after reimplantation. Alternative strategies for these patients are discussed.
引用
- Moser M, Chitta S, O'Brien PF, et al. Recrudescent infection after deep brain stimulator reimplantation. J Neurosurg. 2022. PMID: 35090130. doi:10.3171/2021.11.JNS211425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。